Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)

A multicenter, open-label, dose-escalation phase 1/2 study was undertaken to evaluate the optimal subcutaneous tocilizumab dose that would result in exposure comparable to the intravenous tocilizumab 8-mg/kg approved dose in patients with rheumatoid arthritis. A pharmacokinetic and biomarker approac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohta, Shuji, Tsuru, Tomomi, Terao, Kimio, Mogi, Seiji, Suzaki, Midori, Shono, Eisuke, Ishida, Yoshimasa, Tarumi, Eriko, Imai, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908364/
https://www.ncbi.nlm.nih.gov/pubmed/24115082
http://dx.doi.org/10.1002/jcph.185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908364/
https://www.ncbi.nlm.nih.gov/pubmed/24115082
http://dx.doi.org/10.1002/jcph.185

Ejemplares similares